Atopic dermatitis and skin diseaseTiming and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
Key words
Abbreviations used
Cited by (0)
The funding for ASTERIA I, ASTERIA II, and GLACIAL, as well as this analysis, was provided by Genentech, Inc, South San Francisco, California, and Novartis Pharma AG, Basel, Switzerland. Funding for medical writing support for this manuscript was provided by Genentech, Inc and Novartis Pharmaceuticals Corporation.
Disclosure of potential conflict of interest: A. Kaplan reports having received grants from Dyax, Genentech, Inc, and Shire; personal fees for speaker's bureau activities from Dyax and Shire; and personal fees for consulting activities from CSL Behring and Sanofi-Aventis. M. Ferrer has received research support from Novartis; has received consultancy fees from FAES, Genentech, Inc, and Novartis; and has received lecture fees from MSD. J. A. Bernstein has received research support, consultancy fees, and travel support from Novartis/Genentech, Inc and is a member of the American Academy of Allergy, Asthma & Immunology's Board of Directors. E. Antonova and K. Raimundo are employed by Genentech, Inc. B. Trzaskoma is employed by and has stock/stock options in Genentech, Inc. K. Rosén and J. L. Zazzali are employed by and have stock/stock options in Roche/Genentech, Inc. T. A Omachi was an employee of Roche/Genentech, Inc during the conduct of the study. S. Khalil reports was an employee of Novartis during the conduct of the study.